Asset Details
Do you wish to reserve the book?
Patients carrying
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Patients carrying
Do you wish to request the book?
Patients carrying
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Patients carrying
2018,2019
Overview
First, evaluate if patients carrying putatively diminished activity
genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [T
]). Second, screen additional pharmacogenes for associations with T
.
Pharmacogene panel genotypes were translated into genetic phenotypes for associations with T
(n = 58).
Patients with predicted low-activity CYP2C8 had shorter T
after adjustment for age, body surface area and race (9.65 vs 11.03 hrs, β = 5.47, p = 0.02). This association was attributed to
(p = 0.006), not
(p = 0.58). Patients with predicted low-activity SLCO1B1 had longer T
(12.12 vs 10.15 hrs, β = 0.85, p = 0.012).
Contrary to previous publications,
may confer increased paclitaxel metabolic activity.
and
genotype may explain some paclitaxel pharmacokinetic variability.
Publisher
Future Medicine Ltd
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.